Continued Use of Cholinesterase Inhibitors and Memantine in Hospice.
作者信息
Hunt Lauren J, Gan Siqi, Boscardin W John, Harrison Krista L, Growdon Matthew E, Muench Ulrike U, Gerlach Lauren B, Smith Alexander K, Steinman Michael A
机构信息
Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco.
Department of Epidemiology & Biostatistics, University of California, San Francisco.
出版信息
JAMA Intern Med. 2025 May 1;185(5):595-597. doi: 10.1001/jamainternmed.2024.8579.
Abstract
摘要
相似文献
1
Continued Use of Cholinesterase Inhibitors and Memantine in Hospice.临终关怀中胆碱酯酶抑制剂和美金刚的持续使用。
JAMA Intern Med. 2025 May 1;185(5):595-597. doi: 10.1001/jamainternmed.2024.8579.
2
Discontinuation of Cholinesterase Inhibitors Following Initiation of Memantine and Admission to Long-Term Care Among Older Adults.老年患者启用美金刚后停用胆碱酯酶抑制剂及入住长期护理机构。
JAMA Netw Open. 2024 Nov 4;7(11):e2445878. doi: 10.1001/jamanetworkopen.2024.45878.
3
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.在痴呆症患者中，停用或继续使用胆碱酯酶抑制剂、美金刚或两者。
Cochrane Database Syst Rev. 2021 Feb 3;2(2):CD009081. doi: 10.1002/14651858.CD009081.pub2.
4
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.多奈哌齐、加兰他敏、利伐斯的明和美金刚治疗阿尔茨海默病的有效性和成本效果（技术评估第 111 号回顾）：系统评价和经济模型。
Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210.
5
Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.阿尔茨海默病患者治疗方案的经济评价：成本效益分析的系统评价。
Drugs. 2012 Apr 16;72(6):789-802. doi: 10.2165/11631830-000000000-00000.
6
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.胆碱酯酶抑制剂治疗血管性痴呆和其他血管性认知障碍：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Feb 22;2(2):CD013306. doi: 10.1002/14651858.CD013306.pub2.
7
EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.欧洲神经病学学会（EFNS）-欧洲神经科学学会联合会（ENS）/欧洲神经病学协会（EAN）关于在中度至重度阿尔茨海默病中联合使用胆碱酯酶抑制剂和美金刚的指南。
Eur J Neurol. 2015 Jun;22(6):889-98. doi: 10.1111/ene.12707. Epub 2015 Mar 25.
8
Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.胆碱酯酶抑制剂和盐酸美金刚在帕金森病认知障碍、帕金森病痴呆和路易体痴呆中的疗效和安全性：系统评价和荟萃分析及试验序贯分析。
J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):135-43. doi: 10.1136/jnnp-2014-307659. Epub 2014 May 14.
9
A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.痴呆症药物的风险效益评估：证据的系统综述
Drugs Aging. 2015 Jun;32(6):453-67. doi: 10.1007/s40266-015-0266-9.
10
Cholinesterase inhibitors for dementia with Lewy bodies.用于路易体痴呆的胆碱酯酶抑制剂。
Cochrane Database Syst Rev. 2003;2003(3):CD003672. doi: 10.1002/14651858.CD003672.
本文引用的文献
1
Deprescribing in older people approaching end-of-life: development and validation of STOPPFrail version 2.在接近生命终点的老年人中停用药物：STOPPFrail 版本 2 的制定和验证。
Age Ageing. 2021 Feb 26;50(2):465-471. doi: 10.1093/ageing/afaa159.
2
Older Medicare Beneficiaries Frequently Continue Medications with Limited Benefit Following Hospice Admission.老年医疗保险受益人在入住临终关怀后经常继续使用获益有限的药物。
J Gen Intern Med. 2019 Oct;34(10):2029-2037. doi: 10.1007/s11606-019-05152-x. Epub 2019 Jul 25.
3
Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.在痴呆症中停用胆碱酯酶抑制剂和美金刚：指南摘要。
Med J Aust. 2019 Mar;210(4):174-179. doi: 10.5694/mja2.50015. Epub 2019 Feb 16.
4
Medicare Part D Use of Older Medicare Beneficiaries Admitted to Hospice.医疗保险 D 部分对老年医疗保险受益人入住临终关怀的使用情况。
J Am Geriatr Soc. 2018 May;66(5):937-944. doi: 10.1111/jgs.15328. Epub 2018 Mar 6.
5
Addressing Social Determinants of Health and Health Inequalities.应对健康的社会决定因素和健康不平等问题。
JAMA. 2016 Oct 25;316(16):1641-1642. doi: 10.1001/jama.2016.14058.
Zotero 插件